|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01513 LIVZON PHARMA
Nominal 
39.500 +0.400 (+1.023%) Ranking Overview
Ranking based on 1 research report(s)
Average Ranking 3.00
|
Strong Buy (1)
0
|
Buy (2)
0
|
Hold (3)
1
|
Sell (4)
0
|
Strong Sell (5)
0
|
Previous Financial Performance
| Financial Year | 12/2024 | EPS | 224.00 RMB (cts) | |
| Net Profit | 2,061.10 RMB (MIL) | DPS | 110.00 RMB (cts) |
Consolidation Estimation
| Financial Year | Profit / (Loss) (RMB (MIL)) |
EPS/ ((LPS)(RMB (cts)) |
DPS (RMB (cts)) |
Net Asset Value per Share (RMB) |
Highest (RMB (MIL)) |
Lowest (RMB (MIL)) |
| 2025 | 2,200.00 | 237.00 | 209.00 | -- | 2,200.00 | 2,200.00 |
| 2026 | 2,494.00 | 269.00 | 237.00 | -- | 2,494.00 | 2,494.00 |
| 2027 | 3,043.00 | 328.00 | 289.00 | -- | 3,043.00 | 3,043.00 |
Profit Estimation
| Profit Estimation | Profit / (Loss) (RMB (MIL)) |
EPS*/ (LPS) (RMB (cts)) |
DPS * (RMB (cts)) |
Broker | Ranking | Target Price* (HKD) |
Update Date | |
| 2025 | 2,200.00 | 237.00 | 209.00 | HSBC | Hold | 37.54 | 24/07/2025 | |
| 2026 | 2,494.00 | 269.00 | 237.00 | HSBC | -- | -- | 24/07/2025 | |
| 2027 | 3,043.00 | 328.00 | 289.00 | HSBC | -- | -- | 24/07/2025 | |
| Remarks: | Average rating ranges from 1 to 5. The lower the figure, the higher the rating and the vice versa. |
| *EPS, DPS and Estimated Price would be adjusted upon Consolidation, Split and Bonus Issue | |
| Real time quote last updated: 28/07/2025 17:59 | |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service | |